AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · IEX Real-Time Price · USD
4.490
+0.200 (4.66%)
At close: Mar 27, 2024, 4:00 PM
4.500
+0.010 (0.22%)
Pre-market: Mar 28, 2024, 5:32 AM EDT
Company Description
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development.
Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies.
The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions.
The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics Inc.
Country | Canada |
Founded | 2012 |
IPO Date | Dec 11, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 586 |
CEO | Dr. Carl L.G. Hansen Ph.D. |
Contact Details
Address: 2215 Yukon Street Vancouver, A1 V5Y 0A1 British Columbia, Canada | |
Phone | (604) 559-9005 |
Website | abcellera.com |
Stock Details
Ticker Symbol | ABCL |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $20.00 |
CIK Code | 0001703057 |
CUSIP Number | 00288U106 |
ISIN Number | CA00288U1066 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Carl L.G. Hansen Ph.D. | Chief Executive Officer, President and Chairperson |
Andrew Booth M.B.A. | Chief Financial Officer |
Dr. Veronique Lecault Ph.D. | Chief Operating Officer and Director |
Tryn T. Stimart Esq., J.D., M.Sc. | Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary and Privacy Officer |
Neil Aubuchon B.A., M.B.A. | Chief Commercial Officer |
Marcie Thiessen CPA, CGA | Senior Director of Finance and Accounting |
Dr. Ester Falconer Ph.D. | Chief Technology Officer |
Kathleen Reid B.A. | Head of Corporate Communications |
Graham Craig M.Sc. | Director of Corporate Development |
Murray McCutcheon Ph.D. | Senior Vice President of Partnering |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 23, 2024 | 8-K | Current Report |
Feb 20, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Feb 20, 2024 | 10-K | Annual Report |
Feb 20, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 29, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 28, 2023 | 8-K | Current Report |
Nov 2, 2023 | 10-Q | Quarterly Report |
Nov 2, 2023 | 8-K | Current Report |